"Food and Drug Administration approved one of the drugs for clinical trials,
as New York becomes the epicenter for the pandemic in the U.S.
During a Sunday press briefing, Cuomo said
750,000 doses of chloroquine,
70,000 doses of hydroxychloroquine and
10,000 doses of Zithromax were acquired by New York state for the trial.
Chloroquine (an anti-malaria drug) and hydroxychloroquine (used for lupus and arthritis)
were approved by the FDA for clinical trials as possible coronavirus treatments,
while Zithromax is a brand-name antibiotic"
"Moderna Inc. of Cambridge, Massachusetts, has already begun Phase I human testing
of its mRNA-1273 at Kaiser Permanente Washington Health Research Institute in Seattle.
The test has enrolled 45 healthy adults ages 18 to 55. Phase I will continue over the next six weeks.
The vaccine was developed using part of the genetic sequence from COVID-19 called mRNA, or messenger RNA.
Traditional vaccines use the virus itself; Moderna's mRNA-1273 works off a sequence of the virus' genetic code, instead.
The vaccine is designed to direct the body's cells to produce an antibody — a virus-fighting protein — and spur a robust immune response. It has already shown promise in tests on animals.
Phase I of testing looks at the vaccine's safety and whether it is producing an immune response.
A later phase of research will look at whether the vaccine is effective in preventing infection.
Subjects get an injection on days 1 and 29 and will be followed for 12 months after the second injection.
Regeneron Pharmaceuticals of Tarrytown, New York, is working on an antibody treatment that uses the virus itself.
The company genetically modifies mice to have human immune systems and
then exposes them to part of the virus. The mice then build up antibodies to fight the virus.
Scientists have isolated the antibodies, as well as antibodies from humans who have recovered from COVID-19, and
they will select the top two antibodies to create a cocktail that is injected in the patient.
The two antibodies will target different parts of the virus and may help protect against multiple viral variants.
In theory, that means the drug could still be effective if the virus mutates.
Regeneron's drug could be used as a treatment for those who are already infected,
but according to the company it could also be used as
a preventive measure for the healthy, like a vaccine.
Such drugs are sometimes referred to as "passive" vaccines.
Inovio Pharmaceuticals of Plymouth Meeting, Pennsylvania,
is using an approach similar to Moderna's to develop a vaccine by modeling off the virus' sequence.
Three hours after China published the sequence of the virus online, Inovio developed INO-4800.
Inovio uses something called DNA medicine, which is made up of optimized DNA plasmids.
These are small circles of double-stranded DNA that are reorganized by a computer-sequencing technology and
designed to produce a specific immune response in the body.
Inovio delivers the optimized plasmids directly into the cells,
where they begin replicating and strengthening the body's natural response mechanisms"
the first approved coronavirus drug in China
The National Medical Products Administration of China has approved the use of Favilavir,
an anti-viral drug, as a treatment for coronavirus.
The drug has reportedly shown efficacy in treating the disease with
minimal side effects in a clinical trial involving 70 patients.
The clinical trial is being conducted in Shenzhen, Guangdong province"
An ebola drug developed by Gilead Sciences
that was found to be ineffective is now being tested in two phase III randomised clinical trials in Asian countries.
The trials are being performed on 761 patients in a randomised, placebo-controlled, double-blind study at
multiple hospitals in Wuhan, the epicentre of the novel coronavirus outbreak.
The results from the trials are expected to be available over the next few weeks.
According to a report by The New England Journal of Medicine (NEJM),
remdesivir, when administered to a coronavirus patient in the US, appeared to have improved the clinical condition.
The University of Nebraska Medical Center is also carrying out clinical trials to test the safety and efficacy of the drug.
The first patient to be administered the drug is an evacuee from the Diamond Princess cruise ship.
by Roche to treat coronavirus-related complications
China approved the use of Roche’s Actemra for the treatment of severe complications related to coronavirus.
Drugs like Actemra have the ability to prevent cytokine storms or overreaction of the immune system,
which is considered as the main reason behind organ failure leading to death in some coronavirus patients.
Actemra is also being evaluated in a clinical trial in China, which is expected to enroll 188 coronavirus patients.
The clinical trial is expected to be conducted until May 10.
American Academy of Ophthalmology: https://www.aao.org/headline/alert-important-coronavirus-context
But for her and her colleagues at the Life Care Center and admitting doctors at a nearby hospital,
the eyes became a sign that coronavirus had struck, she told CNN.
"We've had patients that just had the red eyes as the only symptom that we saw and
go to the hospital and pass away," she said.
"I've even had the disaster medical control physician say,
'Do they have the red eyes?' And I will say yes.
And he'll say, 'I'll find you a bed.' It's just something about this,
the way that it affects these patients."
American Academy of Otolaryngology:
Because it attacks the lungs,
the coronavirus that causes COVID-19 could be an especially serious threat to those
who smoke tobacco or marijuana or who vape.
People with opioid use disorder (OUD) and methamphetamine use disorder may also be vulnerable
due to those drugs’ effects on respiratory and pulmonary health.
Additionally, individuals with a substance use disorder are more likely to experience homelessness or
incarceration than those in the general population, and
these circumstances pose unique challenges regarding transmission of the virus that causes COVID-19
New C.D.C. data shows that nearly 40% of patients sick enough to be hospitalized
were age 20 to 54.
But the risk of dying was significantly higher in older people.
Of the 508 patients known to have been hospitalized,
38 percent were notably younger — between 20 and 54.
And nearly half of the 121 patients who were admitted to intensive care units
were adults under 65, the C.D.C. reported.
“I think everyone should be paying attention to this,”